| Elaine C Flint, LPN | |
|
596 W 750 S, Woods Cross, UT 84010-7268 | |
| (801) 298-3919 | |
| Not Available |
| Full Name | Elaine C Flint |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 596 W 750 S, Woods Cross, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982890067 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 146853-3101 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Elaine C Flint, LPN Po Box 618, Farmington, UT 84025-0618 Ph: (801) 451-3315 | Elaine C Flint, LPN 596 W 750 S, Woods Cross, UT 84010-7268 Ph: (801) 298-3919 |
News Archive
Despite their widespread use by parents and caregivers, over-the-counter (OTC) cold and cough medicines have carried a warning by the FDA since 2008, and still have the potential to cause serious adverse events in infants and children. Conservative therapies, including nasal suctioning, humidification, and nasal saline, should be recommended over routine use of OTC cough/cold products in infants and children, according to a new commentary published in the May 2010 issue of Otolaryngology - Head and Neck Surgery.
A new report from the American Cancer Society and other world-leading health groups identifies gaps in research for 20 suspected carcinogens whose potential to cause cancer is as yet unresolved. The report is designed to prioritize agents for additional research, and to lead to well-planned epidemiologic or mechanistic studies leading to more definitive classification of these agents.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
La Jolla Pharmaceutical Company today announced that it has called a special meeting of stockholders for October 30, 2009 for the purpose of voting on a Plan of Complete Liquidation and Dissolution.
Tahitian Noni International's Brett West, director of noni benefits research, and his team have recently published another peer-reviewed paper on the power of iridoids in Tahitian Noni® Bioactives™. The paper, published just this month in the Wiley Online Library, concludes that iridoids are the major source of bioactivity in Tahitian Noni Bioactives, and that substantial iridoids can be found in the noni fruit, leaf, root, seed, and flower of noni plants.
› Verified 4 days ago